The Future of Cannabinoid Pharmaceuticals: Beyond THC and CBD

Minor Cannabinoids: CBG, CBN, THCV, and CBC

• Cannabigerol (CBG) is the biosynthetic precursor to THC and CBD with its own distinct pharmacology
• Cannabinol (CBN) is a degradation product of THC with potential sedative and analgesic properties
• Tetrahydrocannabivarin (THCV) shows appetite-suppressing effects opposite to THC in some research
• Cannabichromene (CBC) has demonstrated anti-inflammatory and potential neuroprotective properties

The focus of medical cannabis research and clinical practice on THC and CBD has obscured the pharmacological richness of the cannabis plant. The plant contains over a hundred identified cannabinoids, many of which have distinct pharmacological profiles and potential therapeutic applications. As analytical chemistry and extraction technologies improve, the pharmaceutical industry is beginning to explore these minor cannabinoids — both as isolated compounds and as part of defined combination products — with serious commercial and clinical intent.

Synthetic Cannabinoids and Novel Molecular Approaches

• Nabilone and dronabinol are approved synthetic cannabinoid pharmaceuticals with established clinical use
• Novel synthetic cannabinoid analogues with improved selectivity and safety profiles are in development
• Peripheral CB2 receptor agonists offer the possibility of cannabinoid therapeutics without central effects
• Allosteric modulators of cannabinoid receptors represent an alternative to direct receptor agonism

The pharmaceutical industry has been working on synthetic cannabinoid compounds for decades, driven by the desire to capture the therapeutic benefits of cannabis whilst eliminating the psychoactive properties associated with THC. Novel molecular approaches — including peripheral CB2 agonists that do not cross the blood-brain barrier and allosteric modulators that modulate receptor function without direct activation — represent a genuinely innovative direction that could produce the next generation of cannabinoid medicines.

Drug Delivery Innovation: From Flower to Pharmaceutical

• Transdermal cannabinoid delivery systems offer controlled, sustained absorption through the skin
• Nanoparticle encapsulation can improve bioavailability and enable targeted tissue delivery
• Oromucosal and sublingual formulations provide rapid onset with reduced first-pass metabolism
• Inhalation delivery technology is advancing towards metered-dose inhaler-style pharmaceutical devices

Drug delivery technology is as important as the active compound in determining the clinical utility of a pharmaceutical. For cannabinoids, where oral bioavailability is variable and inhalation carries respiratory risks, novel delivery systems represent a significant area of pharmaceutical innovation. Transdermal patches, nanoencapsulation, and precision inhalation devices are all being explored as ways to make cannabinoid therapeutics more predictable, reliable, and clinically acceptable in formal healthcare settings.

The Pipeline: Cannabinoid Drugs in Clinical Development

• Several cannabinoid-based medicines are currently in Phase 2 and Phase 3 clinical trials globally
• GW Pharmaceuticals’ pipeline beyond Epidyolex includes compounds targeting multiple neurological conditions
• Rare paediatric epilepsy conditions continue to represent an active clinical development area
• Chronic pain, multiple sclerosis spasticity, and PTSD remain high-priority therapeutic targets

The clinical development pipeline for cannabinoid pharmaceuticals is more active than at any point in the history of the field. Multiple compounds are in advanced clinical trials, and the regulatory pathways established for Epidyolex have demonstrated that cannabinoid medicines can navigate the full pharmaceutical approval process. Companies active in this space should monitor the pipeline closely: new approvals will reshape the medical cannabis landscape, creating both challenges for the unlicensed market and opportunities for those positioned to commercialise or distribute novel cannabinoid pharmaceuticals.